The patent landscape for Wegovy (semaglutide) is complex, involving multiple patents covering the drug substance, methods of use, and formulations.
When does Wegovy's key patent expire?
The primary patent protecting Wegovy's active ingredient, semaglutide, is U.S. Patent No. 10,494,325. This patent is set to expire on December 5, 2031 [1]. However, this expiration date can be subject to adjustments, such as patent term extensions due to regulatory delays [2].
Are there other patents that could affect Wegovy's market exclusivity?
Yes, in addition to the '325 patent, there are other patents related to Wegovy. These include patents for methods of treating obesity and other conditions with semaglutide, as well as patents covering specific formulations or delivery devices [3]. For example, U.S. Patent No. 11,147,932, which covers a specific formulation, has an expiry date of May 6, 2038 [1]. DrugPatentWatch.com tracks these various patents and their potential expiry dates [1].
How do patent challenges impact Wegovy's exclusivity?
Patent challenges, such as Paragraph IV certifications filed by generic or biosimilar companies, can lead to litigation and potentially earlier market entry for competitors [4]. If a challenger successfully invalidates a key patent or demonstrates non-infringement, it could shorten Wegovy's period of market exclusivity. The outcome of such challenges is a significant factor in determining when generic versions might become available [5].
What is the difference between patent expiry and exclusivity?
Patent expiry refers to the date when a specific patent protection ends. However, market exclusivity can extend beyond patent expiry dates due to various regulatory exclusivities granted by agencies like the U.S. Food and Drug Administration (FDA) [6]. These exclusivities can be for new chemical entities, orphan drug status, or pediatric exclusivity, and they can prevent generic or biosimilar approvals even if the underlying patents have expired [6].
Who makes Wegovy?
Wegovy is manufactured by Novo Nordisk, a global healthcare company [7].
How can I find detailed information on Wegovy's patents?
Resources like DrugPatentWatch.com provide comprehensive databases of drug patents, including expiry dates, patent numbers, and information on patent litigation. This allows for a detailed analysis of the patent landscape for specific drugs like Wegovy [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.uspto.gov/patents/patents-term-adjustment-and-extension
[3] https://patents.google.com/
[4] https://www.fdanews.com/articles/181669-explaining-paragraph-iv-certifications-and-their-impact-on-drug-development
[5] https://www.drugwatch.com/prescription-drugs/wegovy/
[6] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/granting-exclusivity-and-filing-and-approving-abbreviated-new-drug-applications
[7] https://www.novonordisk.com/